Focused On-demand Library for Protein YIF1B

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

YIP1-interacting factor homolog B

Alternative UPACC:

Q5BJH7; H7BXS8; Q5JPC2; Q8WY70; Q96C02; Q96IC4


Protein YIF1B, also known as YIP1-interacting factor homolog B, plays a crucial role in cellular transport mechanisms, specifically in the endoplasmic reticulum to Golgi vesicle-mediated transport. It is instrumental in maintaining the proper organization of the endoplasmic reticulum and the Golgi apparatus. Furthermore, YIF1B is vital for the targeting of neuronal dendrites receptors such as HTR1A and is implicated in the assembly of primary cilium and sperm flagellum, highlighting its significance in cellular structure and signaling.

Therapeutic significance:

YIF1B's association with Kaya-Barakat-Masson syndrome, a neurodevelopmental disorder characterized by a spectrum of impairments including intellectual development and motor coordination, underscores its therapeutic significance. Understanding the role of Protein YIF1B could open doors to potential therapeutic strategies for treating or managing this syndrome and possibly other related neurological disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.